ION Breast Cancer Clinical Pathways - ION Solutions

Anti-EmeticsEmetogenic Risk:High Emetic Risk5HT3 or palonosetron hydrochloride; steroid: and aprepitant or fosaprepitantModerate Emetic Risk5HT3 or palonosetron hydrochloride: steroid; +/- aprepitant or fosaprepitantLow Emetic RiskGeneric ondansetron or granisetronMinimal Emetic RiskAgent as listed belowMetaclopramide, lorazepam, prochlorazepine, h2 Blocker or proton pump inhibitor, steroidsand other non-5HT3 or non-aprepitant agents are optional and personalized.Compliance is only for the first cycle of any new line of treatment for chemotherapy forbreast, colon or lung.WBC SupportFebrile Neutropenia Risk:Febrile Neutropenia Risk ˃20%Administer CSFFebrile Neutropenia Risk 65, previous chemotherapy or radiationtherapy, poor performance status, renal or liver impairment, open wounds, preexistingneutropenia, bone marrow metastasis) with documentation.Compliance is only for the first cycle of any new line of treatment for chemotherapy forbreast, colon or lung.Page 36 of 39© 2013 by ION Solutions. All rights reserved